Acadian Asset Management LLC reduced its stake in shares of Enzo Biochem, Inc. (NYSE:ENZ) by 7.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,102,548 shares of the medical research company’s stock after selling 88,257 shares during the period. Acadian Asset Management LLC owned 2.38% of Enzo Biochem worth $12,174,000 at the end of the most recent quarter.
A number of other hedge funds have also recently modified their holdings of the stock. Trexquant Investment LP bought a new position in Enzo Biochem during the first quarter valued at approximately $115,000. Campbell & CO Investment Adviser LLC boosted its position in Enzo Biochem by 24.4% in the first quarter. Campbell & CO Investment Adviser LLC now owns 14,325 shares of the medical research company’s stock valued at $120,000 after buying an additional 2,812 shares during the last quarter. KCG Holdings Inc. bought a new position in Enzo Biochem during the first quarter valued at approximately $141,000. Prudential Financial Inc. bought a new position in Enzo Biochem during the first quarter valued at approximately $149,000. Finally, American International Group Inc. boosted its position in Enzo Biochem by 7.1% in the first quarter. American International Group Inc. now owns 24,432 shares of the medical research company’s stock valued at $204,000 after buying an additional 1,610 shares during the last quarter. Hedge funds and other institutional investors own 62.90% of the company’s stock.
Enzo Biochem, Inc. (NYSE ENZ) traded down 2.00% during trading on Friday, reaching $10.78. 153,647 shares of the company’s stock traded hands. Enzo Biochem, Inc. has a 12 month low of $4.88 and a 12 month high of $12.04. The firm’s 50 day moving average is $11.23 and its 200-day moving average is $9.10. The company has a market capitalization of $500.27 million, a price-to-earnings ratio of 15.12 and a beta of 0.97.
Several equities analysts have commented on ENZ shares. BidaskClub cut shares of Enzo Biochem from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Zacks Investment Research raised shares of Enzo Biochem from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research note on Tuesday, June 20th.
About Enzo Biochem
Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.
What are top analysts saying about Enzo Biochem Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Enzo Biochem Inc. and related companies.